what we’re about

Napo Pharmaceuticals is a wholly owned subsidiary of San Francisco—based Jaguar Health, focusing on developing and commercializing proprietary, plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas.

crofelemer (NP-303) and NP-300

Crofelemer was discovered through the science of ethnobotany, the scientific study of traditional knowledge and customs of local peoples.

This drug is extracted and purified from sangre de drago, the bark sap of the Croton lechleri tree, an abundant, fast-growing Amazonian pioneer tree species widespread in Peru, Colombia, Ecuador, and Bolivia. The tree sap is used by traditional healers working with medicinal plants in these areas. To learn more about the sustainable harvesting of crofelemer, watch our From Tree to Bottle video.

NP-300 is our novel drug product candidate for the symptomatic relief and treatment of moderate to severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral, and parasitic infections, including Vibrio cholerae, the bacterium that causes cholera.

Crofelemer and NP-300 are different botanical drugs extracted and purified from the Croton lechleri tree sap by different processes. Production of crofelemer and NP-300 utilizes practices that prioritize sustainability and conservation of the land from which they are derived.